Chapter 15: TBE vaccines licensed around the globe
Tick-borne encephalitis - The Book · 25.06.2026
DOI: 10.33442/26613980_15-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tick-borne encephalitis - The Book, online erschienen am 25.06.2026. Verfasst von Eva Maria Pöllabauer und 1 weiteren Autor:innen. Die Arbeit nennt 116 Literaturangaben.
Abstract (Originalsprache)
Worldwide there are 6 different TBE vaccines – two from Western Europe, three from Russia and one from China. The two western European vaccines and one of the Russian vaccines have an adult and a pediatric formulation. The products names are FSME IMMUN and FSME-IMMUN Junior; Encepur adults and Encepur children, Klesch-E-Vac, EnceVir and EnceVir Neo, Dry lyophilized TBE Moscow and Sen Tai Bao. All TBE vaccines except the one from China have similar but not identical immunization schedules with primary immunization (3 to 4 doses according to vaccine) and regular booster vaccinations. For FSME-IMMUN, Encepur and EnceVir rapid immunization schedules are also licensed. The Chinese vaccine is given with 2 primary doses 2 weeks apart followed by annual boosters. Both – FSME-IMMUN and Encepur are well tolerated with a well-established safety profile. TBE-Moscow and EnceVir appear to be somewhat more reactogenic. All vaccines induce significant immune responses. In the absence of a formal correlate of protection, the presence of neutralizing antibodies is used as a surrogate marker for protection. More recent investigations indicate that in addition to the presence of neutralizing antibodies, immunologic memory and boostability seem to play a more important role than expected at time of first licensure. Clinical studies show long-term seropersistence of TBE antibodies after the first and subsequent booster vaccination with the two European vaccines. An effectiveness of approximately 99% (years 2000–2006) and 98.7% (years 2000-2011) was calculated for regularly vaccinated persons in Austria, a country with established high vaccination uptake. Recent studies show that vaccine effectiveness (VE) increases gradually with the number of vaccinations and seems to be optimal after 4 and more doses. Booster immunizations every 5 or 3 years, depending on age, are licensed beyond the 4th vaccination for the European vaccines. Recent data from Germany and Switzerland provide some evidence to support extension of booster intervals (up to ten years) for certain parts of the population. Whereas in Western Europe post-exposure prophylaxis with immunoglobulins was discontinued in the late 1990s, due to safety and efficacy concerns, in the highly endemic regions of Russia it continues to be common practice.
Zitieren
APA
Pöllabauer, E. M., & Kollaritsch, H. (2026). Chapter 15: TBE vaccines licensed around the globe. Tick-borne encephalitis - The Book. https://doi.org/10.33442/26613980_15-9
Vancouver
Pöllabauer EM, Kollaritsch H. Chapter 15: TBE vaccines licensed around the globe. Tick-borne encephalitis - The Book. 2026. doi:10.33442/26613980_15-9
BibTeX
@article{Pllabauer2026,
author = {Pöllabauer, Eva Maria and Kollaritsch, Herwig},
title = {Chapter 15: TBE vaccines licensed around the globe},
journal = {Tick-borne encephalitis - The Book},
year = {2026},
doi = {10.33442/26613980_15-9}
}
EUVIMED